On Friday, Pacira BioSciences Inc (NASDAQ: PCRX) opened higher 3.19% from the last session, before settling in for the closing price of $16.95. Price fluctuations for PCRX have ranged from $11.16 to $35.95 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 15.46% annually for the last half of the decade. Company’s average yearly earnings per share was noted 7.35% at the time writing. With a float of $44.59 million, this company’s outstanding shares have now reached $46.48 million.
In an organization with 712 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 67.83%, operating margin of 14.16%, and the pretax margin is 14.57%.
Pacira BioSciences Inc (PCRX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Pacira BioSciences Inc is 3.33%, while institutional ownership is 113.83%. The most recent insider transaction that took place on Sep 13 ’24, was worth 6,430. In this transaction Chief Operating Officer of this company sold 500 shares at a rate of $12.86, taking the stock ownership to the 115,700 shares. Before that another transaction happened on Sep 13 ’24, when Company’s Officer proposed sale 500 for $12.86, making the entire transaction worth $6,430.
Pacira BioSciences Inc (PCRX) Latest Financial update
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted 0.72 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at 0.78) by -0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.35% per share during the next fiscal year.
Pacira BioSciences Inc (NASDAQ: PCRX) Trading Performance Indicators
Check out the current performance indicators for Pacira BioSciences Inc (PCRX). In the past quarter, the stock posted a quick ratio of 5.70. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.17. Likewise, its price to free cash flow for the trailing twelve months is 4.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.29, a number that is poised to hit 0.72 in the next quarter and is forecasted to reach 3.02 in one year’s time.
Technical Analysis of Pacira BioSciences Inc (PCRX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.52 million. That was inferior than the volume of 0.89 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 89.42%. Additionally, its Average True Range was 0.73.
During the past 100 days, Pacira BioSciences Inc’s (PCRX) raw stochastic average was set at 30.89%, which indicates a significant decrease from 98.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 33.04% in the past 14 days, which was lower than the 117.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.57, while its 200-day Moving Average is $24.62. However, in the short run, Pacira BioSciences Inc’s stock first resistance to watch stands at $17.80. Second resistance stands at $18.10. The third major resistance level sits at $18.68. If the price goes on to break the first support level at $16.92, it is likely to go to the next support level at $16.34. The third support level lies at $16.04 if the price breaches the second support level.
Pacira BioSciences Inc (NASDAQ: PCRX) Key Stats
There are currently 46,546K shares outstanding in the company with a market cap of 806.81 million. Presently, the company’s annual sales total 674,980 K according to its annual income of 41,960 K. Last quarter, the company’s sales amounted to 178,020 K and its income totaled 18,890 K.
